title: Outsourcing drug discovery to India and China: from surviving to thriving.
abstract: Global pharmaceutical companies face an increasingly harsh environment for their primary business of selling medicines. They have to contend with a spiraling decline in the productivity of their R&D programs that is guaranteed to severely diminish their growth prospects. Outsourcing of drug discovery activities to low-cost locations is a growing response to this crisis. However, the upsides to outsourcing are capped by the failure of global pharmaceutical companies to take advantage of the full range of possibilities that this model provides. Companies that radically rethink and transform the way they conduct R&D, such as seeking the benefits of low-cost locations in India and China will be the ones that thrive in this environment. In this article we present our views on how the outsourcing model in drug discovery should go beyond increasing the efficiency of existing drug discovery processes to a fundamental rethink and re-engineering of these processes.
authors.affiliation: MSD Pharmaceuticals Pvt Ltd (an affiliate of Merck and Co., Inc., Whitehouse Station, NJ, USA), Platina, 10th Floor, C-59, G-Block, Bandra Kurla Complex, Bandra East, Mumbai 400098, India. swami_subramaniam@merck.com
authors.forename: Swaminathan
authors.initials: S
authors.lastname: Subramaniam
authors.forename: Sundeep
authors.initials: S
authors.lastname: Dugar
mesh_terms: D035843:Biomedical Research; D002681:China; D055808:Drug Discovery; D004345:Drug Industry; D007194:India; D020416:Outsourced Services